JP2014530809A5 - - Google Patents

Download PDF

Info

Publication number
JP2014530809A5
JP2014530809A5 JP2014534535A JP2014534535A JP2014530809A5 JP 2014530809 A5 JP2014530809 A5 JP 2014530809A5 JP 2014534535 A JP2014534535 A JP 2014534535A JP 2014534535 A JP2014534535 A JP 2014534535A JP 2014530809 A5 JP2014530809 A5 JP 2014530809A5
Authority
JP
Japan
Prior art keywords
compound
treated
halogenating agent
solvent
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014534535A
Other languages
English (en)
Japanese (ja)
Other versions
JP6190372B2 (ja
JP2014530809A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/000441 external-priority patent/WO2013052094A2/en
Publication of JP2014530809A publication Critical patent/JP2014530809A/ja
Publication of JP2014530809A5 publication Critical patent/JP2014530809A5/ja
Application granted granted Critical
Publication of JP6190372B2 publication Critical patent/JP6190372B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014534535A 2011-10-07 2012-10-03 抗ウイルスヌクレオチド類似体を調製する方法 Active JP6190372B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61/544,950 2011-10-07
PCT/US2012/000441 WO2013052094A2 (en) 2011-10-07 2012-10-03 Methods for preparing anti-viral nucleotide analogs
US201161544950P 2014-04-11 2014-04-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017083047A Division JP2017160228A (ja) 2011-10-07 2017-04-19 抗ウイルスヌクレオチド類似体を調製する方法

Publications (3)

Publication Number Publication Date
JP2014530809A JP2014530809A (ja) 2014-11-20
JP2014530809A5 true JP2014530809A5 (enExample) 2015-11-19
JP6190372B2 JP6190372B2 (ja) 2017-08-30

Family

ID=47297386

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014534535A Active JP6190372B2 (ja) 2011-10-07 2012-10-03 抗ウイルスヌクレオチド類似体を調製する方法
JP2017083047A Withdrawn JP2017160228A (ja) 2011-10-07 2017-04-19 抗ウイルスヌクレオチド類似体を調製する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017083047A Withdrawn JP2017160228A (ja) 2011-10-07 2017-04-19 抗ウイルスヌクレオチド類似体を調製する方法

Country Status (25)

Country Link
US (4) US8664386B2 (enExample)
EP (2) EP3333173B1 (enExample)
JP (2) JP6190372B2 (enExample)
KR (3) KR20200090975A (enExample)
CN (4) CN113264959A (enExample)
AR (1) AR088109A1 (enExample)
AU (3) AU2012319172B2 (enExample)
BR (2) BR112014011340A2 (enExample)
CA (2) CA2850466C (enExample)
CL (1) CL2014000827A1 (enExample)
CO (1) CO6940431A2 (enExample)
CR (1) CR20140204A (enExample)
EA (1) EA027086B1 (enExample)
EC (1) ECSP14000074A (enExample)
ES (2) ES2661705T3 (enExample)
HK (1) HK1255222B (enExample)
IL (1) IL231879B (enExample)
MX (1) MX353064B (enExample)
PE (1) PE20141160A1 (enExample)
PL (1) PL3333173T3 (enExample)
PT (2) PT2764002T (enExample)
SI (1) SI3333173T1 (enExample)
TW (4) TWI557133B (enExample)
UY (1) UY34361A (enExample)
WO (1) WO2013052094A2 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA115311C2 (uk) 2011-08-16 2017-10-25 Гіліад Сайєнсіз, Інк. Геміфумарат тенофовіру алафенаміду
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
PT2764002T (pt) * 2014-04-11 2018-05-16 Gilead Sciences Inc Métodos para a preparação de análogos de nucleótidos anti-virais
IN2013MU01967A (enExample) * 2013-06-07 2015-06-12 Cipla Ltd
CN104628773B (zh) * 2013-11-06 2018-10-23 杭州和泽医药科技有限公司 (r)-9-[2-(磷酰苯酚基甲氧基)丙基]腺嘌呤的制备方法
IN2013CH05455A (enExample) * 2013-11-27 2015-08-07 Laurus Labs Private Ltd
IN2014MU00118A (enExample) * 2014-01-14 2015-08-28 Mylan Lab Ltd
TWI660965B (zh) 2014-01-15 2019-06-01 美商基利科學股份有限公司 泰諾福韋之固體形式
CN105531281B (zh) * 2014-04-21 2017-12-15 四川海思科制药有限公司 一种核苷类似物及其中间体的制备方法
CN105518012B (zh) * 2014-06-25 2018-03-02 四川海思科制药有限公司 一种取代的氨基酸硫酯类化合物、其组合物及应用
CN105399771B (zh) * 2014-07-21 2020-11-24 江苏豪森药业集团有限公司 替诺福韦前药晶型及其制备方法和用途
CN108148094A (zh) * 2014-11-12 2018-06-12 四川海思科制药有限公司 一种替诺福韦艾拉酚胺富马酸盐晶型c及其制备方法和用途
CN104817593B (zh) * 2015-04-27 2016-11-16 广州同隽医药科技有限公司 半富马酸替诺福韦艾拉酚胺关键中间体的合成工艺
PE20231843A1 (es) 2015-08-05 2023-11-21 Eisai Randd Man Co Ltd Reactivos quirales para la preparacion de oligomeros homogeneos
TWI616452B (zh) * 2015-08-26 2018-03-01 Preparation method of nucleoside analog and intermediate thereof
CN105330700A (zh) * 2015-12-17 2016-02-17 中国药科大学 富马酸替诺福韦艾拉酚胺杂质的制备方法
WO2017118928A1 (en) 2016-01-06 2017-07-13 Lupin Limited Process for the separation of diastereomers of tenofovir alafenamide
CZ2016156A3 (cs) * 2016-03-17 2017-09-27 Zentiva, K.S. Způsob přípravy diastereomerně čistého Tenofoviru Alafenamidu nebo jeho solí
CN107286190A (zh) * 2016-04-13 2017-10-24 刘沛 核苷之烃氧基苄基氨基磷酸/膦酸酯衍生物的制备及其医药用途
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN106565785B (zh) * 2016-11-09 2019-11-12 周雨恬 一种具有抗hbv/hiv活性的核苷氨基磷酸酯类化合物及其盐和用途
CN106946935B (zh) * 2017-04-28 2020-01-07 福建广生堂药业股份有限公司 一种非对映异构体核苷衍生物的制备方法
CN118440096A (zh) 2017-06-20 2024-08-06 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
JP2020536100A (ja) * 2017-10-04 2020-12-10 セルジーン コーポレイション シス−4−[2−{[(3s,4r)−3−フルオロキサン−4−イル]アミノ}−8−(2,4,6−トリクロロアニリノ)−9h−プリン−9−イル]−1−メチルシクロヘキサン−1−カルボキサミドの製造プロセス
CN109942633B (zh) * 2017-12-20 2021-08-31 上海新礼泰药业有限公司 替诺福韦艾拉酚胺中间体的制备方法
CN109942632B (zh) * 2017-12-20 2021-08-31 上海博志研新药物研究有限公司 替诺福韦艾拉酚胺中间体的制备方法
CN110092803A (zh) * 2018-01-31 2019-08-06 北京睿创康泰医药研究院有限公司 替诺福韦艾拉酚胺富马酸盐工艺杂质的制备及其应用
CN108409788B (zh) * 2018-03-12 2020-05-08 科兴生物制药股份有限公司 一种富马酸替诺福韦艾拉酚胺的制备方法
CN110305163A (zh) * 2018-03-27 2019-10-08 北京济美堂医药研究有限公司 替诺福韦艾拉酚胺半富马酸盐的制备方法
CN108467410B (zh) * 2018-04-09 2021-04-09 重庆三圣实业股份有限公司 一种taf中间体的制备方法及产品和应用
CN108484672A (zh) * 2018-05-23 2018-09-04 中国药科大学制药有限公司 磷丙替诺福韦的手性拆分方法
CN108822149B (zh) * 2018-06-01 2020-08-11 成都苑东生物制药股份有限公司 一种富马酸替诺福韦艾拉酚胺关键中间体的制备方法
CN110283208B (zh) * 2018-06-22 2022-07-08 南京济群医药科技股份有限公司 一种替诺福韦艾拉酚胺的手性拆分方法
CN109081853A (zh) * 2018-09-03 2018-12-25 南京正大天晴制药有限公司 一种磷丙替诺福韦有关物质的制备方法
CN111484527A (zh) * 2019-01-25 2020-08-04 上海清松制药有限公司 一种替诺福韦艾拉酚胺中间体的制备方法
WO2020197991A1 (en) 2019-03-22 2020-10-01 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
CN111943981A (zh) * 2019-05-14 2020-11-17 博瑞生物医药泰兴市有限公司 一种磷丙替诺福韦的制备方法
CN114409706B (zh) * 2019-07-01 2023-11-28 上海医药工业研究院 一种苯基氢膦酸酯及其中间体的制备方法
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
CN112390824B (zh) * 2019-08-19 2022-07-05 鲁南制药集团股份有限公司 一种替诺福韦艾拉酚胺中间体的制备方法
CN110981911A (zh) * 2019-10-08 2020-04-10 浙江车头制药股份有限公司 一种替诺福韦艾拉酚胺的制备方法
CN111171076A (zh) * 2019-12-26 2020-05-19 合肥启旸生物科技有限公司 一种替诺福韦二聚体的制备方法
AR121620A1 (es) 2020-03-20 2022-06-22 Gilead Sciences Inc Profármacos de nucleósidos 4’-c-sustituidos-2-halo-2’-deoxiadenosina y métodos de preparación y uso de los mismos
KR20210125298A (ko) 2020-04-08 2021-10-18 주식회사 파마코스텍 테노포비어 알라펜아미드 헤미타르트레이트의 신규한 제조방법
PT4244396T (pt) 2020-11-11 2025-10-20 Gilead Sciences Inc Métodos de identificação de doentes com hiv sensíveis à terapia com anticorpos dirigidos ao sítio de ligação cd4 da gp120
KR20220141457A (ko) 2021-04-13 2022-10-20 경동제약 주식회사 신규 결정형의 테노포비어 알라펜아미드 말레산염 및 이를 포함하는 약제학적 조성물
PL4445900T3 (pl) 2021-12-03 2025-09-22 Gilead Sciences, Inc. Związki terapeutyczne przeciwko zakażeniu wirusem hiv
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
TW202434566A (zh) 2022-07-01 2024-09-01 美商基利科學股份有限公司 可用於hiv病毒感染之疾病預防性或治療性治療的治療性化合物
CA3265134A1 (en) 2022-08-26 2024-02-29 Gilead Sciences Inc DOSING AND PLANNING REGIMEN FOR BROADLY NEUTRALIZING ANTIBODIES
EP4598934A1 (en) 2022-10-04 2025-08-13 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
AU2024259111A1 (en) 2023-04-19 2025-10-16 Gilead Sciences, Inc. Dosing regimen of capsid inhibitor
US20250011352A1 (en) 2023-05-31 2025-01-09 Gilead Sciences, Inc. Solid forms
TW202448483A (zh) 2023-05-31 2024-12-16 美商基利科學股份有限公司 用於hiv之治療性化合物
WO2025029247A1 (en) 2023-07-28 2025-02-06 Gilead Sciences, Inc. Weekly regimen of lenacapavir for the treatment and prevention of hiv
WO2025042394A1 (en) 2023-08-23 2025-02-27 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
US20250122219A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
US20250127801A1 (en) 2023-10-11 2025-04-24 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
US20250120989A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2025137245A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
WO2025184609A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Antiviral compounds
US20250289822A1 (en) 2024-03-01 2025-09-18 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
US20250296932A1 (en) 2024-03-01 2025-09-25 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2682397B1 (en) * 2000-07-21 2017-04-19 Gilead Sciences, Inc. Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
US20050239054A1 (en) 2002-04-26 2005-10-27 Arimilli Murty N Method and compositions for identifying anti-HIV therapeutic compounds
ES2363160T3 (es) 2004-07-27 2011-07-22 Gilead Sciences, Inc. Conjugados de fosfonato nucelosidico como agentes anti-vih.
EA020088B1 (ru) * 2006-03-29 2014-08-29 Джилид Сайэнс, Инк. Способ получения производных бисфуранового спирта, соединения, соль, фармацевтическая композиция на ее основе, способ лечения или профилактики ретровирусных инфекций с ее помощью
US8338593B2 (en) * 2006-07-07 2012-12-25 Gilead Sciences, Inc. Modulators of toll-like receptor 7
CA2657821A1 (en) * 2006-07-21 2008-01-24 Gilead Sciences, Inc. Aza-peptide protease inhibitors
AP2514A (en) * 2006-07-24 2012-11-23 Korea Res Inst Chem Tech HIV reverse transcriptase inhibitors
KR20100041798A (ko) * 2007-06-29 2010-04-22 한국화학연구원 신규 hiv 역전사효소 억제제
UA115311C2 (uk) 2011-08-16 2017-10-25 Гіліад Сайєнсіз, Інк. Геміфумарат тенофовіру алафенаміду
PT2764002T (pt) 2014-04-11 2018-05-16 Gilead Sciences Inc Métodos para a preparação de análogos de nucleótidos anti-virais

Similar Documents

Publication Publication Date Title
JP2014530809A5 (enExample)
JP6190372B2 (ja) 抗ウイルスヌクレオチド類似体を調製する方法
Turcheniuk et al. Efficient asymmetric synthesis of trifluoromethylated β-aminophosphonates and their incorporation into dipeptides
HK1255222A1 (en) Methods for preparing anti-viral nucleotide analogs
KR101616945B1 (ko) 라세믹 또는 광학적으로 활성이 있는 α―글리세로포스포릴 콜린의 제조방법
ES2706319T3 (es) Un método de preparación de gadobutrol
CN103554175A (zh) 一种试剂制备方法
JP2007091605A (ja) クロロエチレンカーボネートの製造方法
ES2265383T3 (es) Metodo para purificar un compuesto metalico de fluoroarilo.
HK40052309A (en) Methods for preparing anti-viral nucleotide analogs
ES2546362A2 (es) PROCEDIMIENTO DE OBTENCIÓN DEL ÁCIDO (S) -2 BENCIL 4 - ((3aR, 7aS) -HEXAHIDRO-1H-ISOINDOL-2 (3H) IL) -4-OXOBUTANOICO Y SUS SALES
EP2900663A2 (en) Process for the preparation of rivaroxaban
HK1245798B (zh) 制备抗病毒核苷酸类似物的方法
Dzhavakhiya Synthesis of Alafosfalin (V) and Its Phosphinic Analogue and Their Fungicidal Activity